Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bis-choline tetrathiomolybdate - Alexion Pharmaceuticals

Drug Profile

Bis-choline tetrathiomolybdate - Alexion Pharmaceuticals

Alternative Names: ALXN1840; ATN-224; Decuprate; WTX-101

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Attenuon LLC
  • Developer Alexion Pharmaceuticals; Attenuon; Cancer Research UK
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatolenticular degeneration
  • Preclinical Amyotrophic lateral sclerosis
  • Discontinued Breast cancer; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 26 Jul 2018 Wilson Therapeutics has been acquired by Alexion Pharmaceuticals
  • 24 Jun 2018 Biomarkers information updated
  • 12 Apr 2018 Long-term extension data from a phase II trial in Wilson's disease released by Wilson Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top